Stryker Corp (SYK): EBITDA
$6.46B
Year ended 2025-12-31
+16.2%
3-year compound annual growth
+14.4%
5-year compound annual growth
+10.2%
10-year compound annual growth
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.46B | +26.3% | 2026-02-11, From 2025-01-01 |
| 2024-12-31 | $5.12B | -2.2% | 2026-02-11, From 2024-01-01 |
| 2023-12-31 | $5.23B | +26.9% | 2026-02-11, From 2023-01-01 |
| 2022-12-31 | $4.12B | +6.8% | 2025-02-12, From 2022-01-01 |
| 2021-12-31 | $3.86B | +16.9% | 2024-02-14, From 2021-01-01 |
| 2020-12-31 | $3.30B | -12.2% | 2023-02-10, From 2020-01-01 |
| 2019-12-31 | $3.76B | +7.3% | 2022-02-11, From 2019-01-01 |
| 2018-12-31 | $3.50B | +11.0% | 2021-02-11, From 2018-01-01 |
| 2017-12-31 | $3.16B | +7.8% | 2020-02-06, From 2017-01-01 |
| 2016-12-31 | $2.93B | +19.4% | 2019-02-07, From 2016-01-01 |
| 2015-12-31 | $2.45B | +33.8% | 2018-02-08, From 2015-01-01 |
| 2014-12-31 | $1.83B | +3.7% | 2017-02-09, From 2014-01-01 |
| 2013-12-31 | $1.77B | -20.7% | 2016-02-11, From 2013-01-01 |
| 2012-12-31 | $2.23B | +2.8% | 2015-02-12, From 2012-01-01 |
| 2011-12-31 | $2.17B | +0.3% | 2014-02-13, From 2011-01-01 |
| 2010-12-31 | $2.16B | +9.2% | 2013-02-27, From 2010-01-01 |
| 2009-12-31 | $1.98B | n/a | 2012-02-13, From 2009-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Stryker Corp (SYK) | 2025-12-31 | $6.46B | +26.3% |
| 3M Co (MMM) | 2025-12-31 | $5.94B | -4.0% |
| Medline Inc. (MDLN) | 2025-12-31 | $3.22B | +3.2% |
| Becton Dickinson & Co (BDX) | 2025-09-30 | $5.04B | +7.6% |
| Boston Scientific Corp (BSX) | 2025-12-31 | $4.98B | +28.6% |
| Baxter International Inc (BAX) | 2025-12-31 | $673.00M | -33.4% |
| Solventum Corp (SOLV) | 2025-12-31 | $2.67B | +67.8% |
| ResMed Inc (RMD) | 2026-06-30 | $2.09B | +10.8% |
| Dexcom Inc (DXCM) | 2025-12-31 | $1.16B | +42.3% |
Compare SYK, MMM, MDLN, BDX side by side · Screen every company in Surgical & Medical Instruments & Apparatus ↗